The applied testing market will represent a $5 billion opportunity by 2008, and Qiagen expects its preanalytical technologies to play a significant role in that segment, CEO Peer Schatz said during a presentation to analysts and investors in New York last week.

Even though this market currently represents around half of Qiagen's total sales, Schatz said the firm will remain primarily focused on growing its molecular diagnostics business.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.